Dr. Goldsmith is Founding President, CEO and Board Chairman of Revolution Medicines. He previously was Partner with Third Rock Ventures in its West Coast office. Prior to Third Rock, Dr. Goldsmith served in senior management roles in private and public biotechnology companies. He was President and Chief Executive Officer of Constellation Pharmaceuticals from 2009 to 2012, and since 2012 has been the company’s Board Chairman. He was the first CEO of both Global Blood Therapeutics and Nurix Therapeutics, as well as CEO of Cogentus Pharmaceuticals and Senior Vice President of Genencor International. He also served as senior executive-in-residence at Prospect Venture Partners. After postgraduate training at the Brigham and Women’s Hospital/Harvard Medical School and UCSF, Mark joined the faculty of the UCSF School of Medicine, led a dynamic research laboratory within the Gladstone Institute of Virology and Immunology and taught and practiced medicine at the San Francisco General Hospital/UCSF. He has co-authored 85 scientific publications and is co-inventor on multiple issued patents and applications. Mark holds an AB from Princeton University and an MD and PhD in microbiology and immunology from UCSF. He was elected to the American Society for Clinical Investigation and the Association of American Physicians.